| Proteogenomic and metabolomic characterization of human glioblastoma LB Wang, A Karpova, MA Gritsenko, JE Kyle, S Cao, Y Li, D Rykunov, ... Cancer Cell 39 (4), 509-528. e20, 2021 | 390 | 2021 |
| Proteogenomic data and resources for pan-cancer analysis Y Li, Y Dou, FDV Leprevost, Y Geffen, AP Calinawan, F Aguet, Y Akiyama, ... Cancer Cell 41 (8), 1397-1406, 2023 | 24 | 2023 |
| Pan-cancer proteogenomics connects oncogenic drivers to functional states Y Li, E Porta-Pardo, C Tokheim, MH Bailey, TM Yaron, V Stathias, ... Cell 186 (18), 3921-3944. e25, 2023 | 19 | 2023 |
| Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation Y Geffen, S Anand, Y Akiyama, TM Yaron, Y Song, JL Johnson, ... Cell 186 (18), 3945-3967. e26, 2023 | 18 | 2023 |
| Multimodal single‐cell analysis reveals distinct radioresistant stem‐like and progenitor cell populations in murine glioma J Alexander, QC LaPlant, SS Pattwell, F Szulzewsky, PJ Cimino, ... Glia 68 (12), 2486-2502, 2020 | 10 | 2020 |
| BayesDeBulk: a flexible bayesian algorithm for the deconvolution of bulk tumor data F Petralia, A Krek, AP Calinawan, S Feng, S Gosline, P Pugliese, ... bioRxiv, 2021.06. 25.449763, 2021 | 8 | 2021 |
| Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin WW Liang, RJH Lu, RG Jayasinghe, SM Foltz, E Porta-Pardo, Y Geffen, ... Cancer Cell 41 (9), 1567-1585. e7, 2023 | 7 | 2023 |
| Pan-cancer proteogenomics characterization of tumor immunity F Petralia, W Ma, TM Yaron, FP Caruso, N Tignor, JM Wang, ... Cell, 2024 | 5 | 2024 |
| Decomprolute is a benchmarking platform designed for multiomics-based tumor deconvolution S Feng, A Calinawan, P Pugliese, P Wang, M Ceccarelli, F Petralia, ... Cell Reports Methods 4 (2), 2024 | 2 | 2024 |
| Deep learning integrates histopathology and proteogenomics at a pan-cancer level JM Wang, R Hong, EG Demicco, J Tan, R Lazcano, AL Moreira, Y Li, ... Cell Reports Medicine 4 (9), 2023 | 1 | 2023 |
| Abstract LB004: Deciphering oncogenic dedifferentiation: A proteomic approach to quantifying stemness scores and unveiling druggable targets I Kołodziejczak-Guglas, R Simões, EG Demicco, RL Segura, AJ Lazar, ... Cancer Research 84 (7_Supplement), LB004-LB004, 2024 | | 2024 |
| P12. 08. A CELL-EXTRINSIC D-2-HYDROXYGLUTARATE PROMOTES HYPERMETHYLATION AT LINEAGE-SPECIFIC REGULATORY REGIONS TO PREVENT MICROGLIAL ACTIVATION IN IDH-MUTANT GLIOMAS A Laurenge, P Pugliese, Q Richard, A Picca, S Jouannet, K Labreche, ... Neuro-Oncology 25 (Supplement_2), ii98-ii98, 2023 | | 2023 |
| Abstract LB061: Proteomic-based stemness score measure oncogenic dedifferentiation and enable the identification of druggable targets TM Malta, I Kołodziejczak, R Simões, A Colaprico, E Storrs, F Petralia, ... Cancer Research 83 (8_Supplement), LB061-LB061, 2023 | | 2023 |
| Pan-cancer stemness defined by CPTAC proteogenomics guides personalized therapies M Wiznerowicz, A Colaprico, E Storrs, F Petralia, I Kołodziejczak, ... Cancer Research 81 (13_Supplement), 3113-3113, 2021 | | 2021 |
